Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Hims & Hers vs Trimrose

Hims & Hers
Graded #36

Higher grade

vs+25.799999999999997
Trimrose
Graded #446

Lower grade

The verdict

Hims & Hers takes it — 81/100 to 55.2/100.

Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHims & Hers +43
82
39
Dose & formulationHims & Hers +14
78
64
Clinical oversightHims & Hers +14
82
68
Labs & monitoringHims & Hers +28
80
52
FulfillmentHims & Hers +27
84
57
Contract termsHims & Hers +25
80
55
Hims & Hers · left barTrimrose · right bar

The numbers

MetricHims & HersTrimrose
WeighScore81/10055.2/100
GradeB−C
Scorecard rank#36#446
Semaglutide$199/moNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Hims & Hers

Graded #36 · B−

Strengths

  • Nationwide
  • Polished app
  • Strong brand trust

Where it loses points

  • Tirzepatide pricing inconsistently disclosed
  • Industry-wide compounding scrutiny
Trimrose

Graded #446 · C

Strengths

  • Free, no-cost, no-obligation online eligibility quiz before any commitment
  • Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
  • Fully online — assessment, provider review, and home delivery with ongoing support

Where it loses points

  • Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
  • Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
  • The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
  • Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard